ANIP vs VTRS
ANIP: A diversified biopharmaceutical company focused on growing its Rare Disease, Brands, and Generics segments through a combination of internal development and strategic acquisitions. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | ANIP | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $78.25 | $16.43 | |
| Market cap as of 2026-08-09 | $1.9B | $19.1B | |
| P/E as of 2026-08-09 | 19.31 | n/a | |
| PEG as of 2026-08-09 | 1.13 | 1.68 | ANIP lower |
| Net margin as of 2026-08-09 | +10.0% | -2.8% | ANIP higher |
| Gross margin as of 2026-08-09 | +60.8% | +40.3% | ANIP higher |
| Operating margin as of 2026-08-09 | +13.4% | -0.9% | ANIP higher |
| ROE as of 2026-08-09 | +17.8% | -2.8% | ANIP higher |
| ROA as of 2026-08-09 | +6.6% | -1.1% | ANIP higher |
| Debt / equity as of 2026-08-09 | 1.09 | 0.94 | VTRS lower |
| Revenue growth (YoY) as of 2026-08-09 | +37.0% | +4.4% | ANIP higher |
| Revenue CAGR (3y) SEC XBRL | +40.8% | -4.2% | ANIP higher |
| Dividend yield as of 2026-08-09 | +0.0% | +2.7% | VTRS higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-09 | 0.51 | 0.87 | |
| 1-year return as of 2026-08-07 close | +13.4% | +75.0% | VTRS higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.